Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II trial of Tavokinogene telsaplasmid in combination with standard of care pembrolizumab and another immunotherapy in the recurrent and/or metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Trial Profile

A Phase II trial of Tavokinogene telsaplasmid in combination with standard of care pembrolizumab and another immunotherapy in the recurrent and/or metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Planning
Phase of Trial: Phase II

Latest Information Update: 06 Jul 2018

At a glance

  • Drugs Tavokinogene telsaplasmid (Primary)
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 06 Jul 2018 New trial record
    • 28 Jun 2018 According to an OncoSec Medical media release, the company plans to initiate this trial during the second half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top